Form 4: Opaleye Management Inc. Reduces Stake in Protara Therapeutics

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held by Opaleye, L.P. and a managed account.

Summary

• Opaleye Management Inc., a 10% owner of Protara Therapeutics, Inc. (TARA), filed a Form 4 detailing changes in beneficial ownership.
• On July 16, 2024, Opaleye Management Inc. sold 7,896 shares of common stock at a weighted average price of $2.4419 per share, reducing its holdings through Opaleye, L.P.
• Additionally, 3,500 shares were sold from a managed account at the same weighted average price.
• Following these transactions, Opaleye, L.P. beneficially owns 2,153,527 shares, and the managed account owns 56,500 shares.
• The sales were executed in multiple transactions with prices ranging from $2.4397 to $2.5125.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in holdings by a major shareholder, which could indicate a lack of confidence in the company's future prospects. However, without further context, it's difficult to assess the full impact.

Negatives

• Opaleye Management Inc., a significant shareholder, reduced its stake in Protara Therapeutics.

Risks

• Continued selling pressure from major shareholders could negatively impact the stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders trade shares of a publicly traded company. These filings are closely watched by investors for insights into the sentiment and actions of those with privileged information.

Comparison to Industry Standards

• Comparing Opaleye's transactions to similar filings from other biotech firms like Amgen or Gilead Sciences would provide context on whether this selling activity is typical or unusual.
• Analyzing the trading patterns of other major shareholders in Protara Therapeutics could reveal whether this is an isolated event or part of a broader trend.
• Benchmarking the transaction prices against the average trading volume and price volatility of TARA stock can help assess the impact of these sales on the market.

Stakeholder Impact

• Shareholders may react negatively to the news of a major shareholder reducing their stake.
• The stock price could experience downward pressure in the short term.

Key Dates